Mark W. Hahn logo

Mark W. Hahn

North America, North Carolina, United States, Chapel Hill

Description

Mark W. Hahn is the Chief Financial Officer of Verona Pharma. Mr. Hahn holds a Bachelor of Business Administration degree in Accounting and...

Investor Profile

Mark W. Hahn has made 1 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Post Ipo Equity (100%)

Country Focus

  • United Kingdom (100%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Mark W. Hahn frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 1
Abingworth
Europe, England, United Kingdom, London
Co-Investments: 1
Access Biotechnology
North America, New York, United States, New York
Co-Investments: 1
PBM Capital Group
North America, Virginia, United States, Charlottesville
Co-Investments: 1
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 1
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 1
Fairmount Funds Management
North America, Pennsylvania, United States, Philadelphia
Co-Investments: 1
Foresite Capital
North America, California, United States, San Francisco
Co-Investments: 1
Acorn Bioventures
North America, New York, United States, New York
Co-Investments: 1
Aisling Capital
North America, New York, United States, New York
Co-Investments: 1

Which angels does Mark W. Hahn often collaborate with?

ME
Europe, England, United Kingdom
Shared Deals: 1
AU
Europe, Hallands Lan, Sweden, Kungsbacka
Shared Deals: 1
VS
North America, Massachusetts, United States, Boston
Shared Deals: 1
David Zaccardelli
North America, United States
Shared Deals: 1
DE
Europe, Zurich, Switzerland, Zürich
Shared Deals: 1

What are some of recent deals done by Mark W. Hahn?

Verona Pharma

London, England, United Kingdom

Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases.

BiotechnologyPharmaceuticalTherapeutics
Post Ipo EquityJul 17, 2020
Amount Raised: $200,000,000